Home › Compare › SPNZF vs ABBV
SPNZF yields 3.23% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, SPNZF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SPNZF + ABBV for your $10,000?
South Port New Zealand Limited operates and manages a port in New Zealand. It offers marine services, including shipping movements, pilotage and procedures, cruise schedules, marine plant and equipment, wind and tide conditions, syncrolift, and hot work; port facilities, such as port infrastructure; berths; infrastructure and land; plant and equipment; and weighbridge services; container servicing and rates, and container tracking services; and cold storage and dry warehousing services. The company also provides full container, break bulk, and bulk cargo capability and services for the import of alumina, petroleum products, fertilizers, acids, stock food, and cement; and the export of aluminum, timber, logs, dairy, meat by-products, fish, and woodchips. In addition, it handles project cargo, such as transformer weighing; wind farm material, which include twin cranes lifts and a maximum lift of 80 metric tonnes; hydroelectric power station tail race equipment; mining equipment that comprise bucket wheel excavators and dump trucks; tanks for tallow storage, as well as a range of machinery, including pleasure and fishing vessels; and operates intermodal freight center. South Port New Zealand Limited was incorporated in 1988 and is based in Bluff, New Zealand.
Full SPNZF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.